Clinical Exploration of Immunosuppressants Combined with Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer  

作　　者：Lin Ma 

机构地区：[1]Zhangjiakou First Hospital,Zhangjiakou 075000,Hebei Province,China

出　　处：《Journal of Clinical and Nursing Research》2024年第5期124-128,共5页临床护理研究（英文）

摘　　要：Prostate cancer is a malignant tumor with a high incidence in elderly men.In recent years,with the improvement of people’s living standards and the advancement of detection technology,the incidence of prostate cancer has been increasing year by year.Castration-resistant prostate cancer(CRPC)is a highly challenging type of advanced prostate cancer treatment,which clinically shows resistance to hormonal deprivation therapy.The overall treatment efficacy of CRPC is currently poor and further relevant therapeutic studies are needed to improve patient survival and quality of life.Immunosuppressants can play a role in combating the immune system of tumors,and abiraterone has also achieved remarkable results in prostate cancer treatment.This study will investigate the possible clinical effects and safety of immunosuppressants combined with abiraterone in the treatment of metastatic CRPC.The population-based study will provide clinicians with more effective treatment options,as well as enhance the understanding of novel combination therapy strategies to be implemented in the future for such patients.

关 键 词：IMMUNOSUPPRESSANTS ABIRATERONE Prostate cancer Immune system 

分 类 号：R73[医药卫生—肿瘤]